Aspiriant LLC Has $258,000 Stock Position in Solventum Co. (NYSE:SOLV)

Aspiriant LLC cut its holdings in shares of Solventum Co. (NYSE:SOLV) by 4.0% in the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 3,705 shares of the company’s stock after selling 156 shares during the quarter. Aspiriant LLC’s holdings in Solventum were worth $258,000 as of its most recent SEC filing.

Several other hedge funds also recently modified their holdings of the business. Price T Rowe Associates Inc. MD acquired a new position in Solventum during the 1st quarter valued at $5,889,000. Mitsubishi UFJ Trust & Banking Corp bought a new stake in shares of Solventum in the first quarter valued at about $5,747,000. CWM LLC acquired a new stake in Solventum during the second quarter worth about $473,000. Great Valley Advisor Group Inc. bought a new position in Solventum during the second quarter valued at about $493,000. Finally, First Horizon Advisors Inc. acquired a new position in Solventum in the 2nd quarter valued at approximately $58,000.

Solventum Stock Up 1.8 %

Shares of SOLV stock opened at $73.68 on Friday. Solventum Co. has a 12-month low of $47.16 and a 12-month high of $96.05. The company has a debt-to-equity ratio of 2.90, a current ratio of 1.31 and a quick ratio of 0.96. The firm has a 50-day moving average price of $66.13 and a 200 day moving average price of $61.10.

Solventum (NYSE:SOLV) last posted its earnings results on Thursday, August 8th. The company reported $1.56 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.46 by $0.10. The firm had revenue of $2.08 billion during the quarter, compared to the consensus estimate of $2.05 billion. The company’s quarterly revenue was up .2% compared to the same quarter last year. On average, research analysts predict that Solventum Co. will post 6.38 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

A number of analysts have recently issued reports on the company. BTIG Research assumed coverage on Solventum in a research report on Thursday, September 5th. They set a “neutral” rating on the stock. Wolfe Research started coverage on shares of Solventum in a report on Thursday, September 26th. They issued a “peer perform” rating on the stock. Bank of America reduced their price objective on shares of Solventum from $70.00 to $60.00 and set a “neutral” rating for the company in a report on Tuesday, June 25th. Wells Fargo & Company lowered their target price on shares of Solventum from $69.00 to $64.00 and set an “equal weight” rating on the stock in a research note on Friday, August 9th. Finally, Argus began coverage on shares of Solventum in a research note on Monday, June 24th. They set a “hold” rating for the company. One investment analyst has rated the stock with a sell rating, eight have given a hold rating and one has assigned a buy rating to the stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and a consensus price target of $64.33.

Solventum Company Profile

Solventum Corporation, a healthcare company, engages in the developing, manufacturing, and commercializing a portfolio of solutions to address critical customer and patient needs. It operates through four segments: Medsurg, Dental Solutions, Health Information Systems, and Purification and Filtration.